China-based robotic and digital technologies provider Ronovo Surgical has secured $67m in its Series D funding round, led by Johnson & Johnson’s venture capital arm, JJDC.
Other participants in the funding round include Lilly Asia Ventures, INCE Capital, and Granite Asia.
It is the company’s second financing round in 2025, following the Series C round led by Granite Asia, bringing its total investment to $100m this year.
In addition to the Series D round, Ronovo Surgical has partnered with Johnson & Johnson Medical Shanghai to enhance surgical technology accessibility in China.
Under the partnership agreement, Ronovo Surgical will offer hospitals in China with Carina platform alongside Johnson & Johnson’s MedTech solutions.
Carina, already approved by China’s national medical products administration (NMPA), is the nation’s first modular robotic system for multiple surgical specialities.
The platform, with a modular design, has secured positive feedback from international experts, which support its potential to meet global healthcare demands, said the company.
Furthermore, Ronovo Surgical is filing for regulatory approval in Europe and South America.
Ronovo Surgical founder, chairman, and CEO John Ma said: “We are grateful for the successful closing of our Series D round led by JJDC.
“Carina—flexible, adaptable, and affordable—embodies our commitment to democratizing access to surgical robotics on a global scale.
“We’re excited about the strategic collaboration with Johnson & Johnson MedTech, which will further accelerate our commercial momentum in China while laying the foundation for international growth.”
In June last year, Ronovo Surgical closed its Series B funding, raising $44m to further commercialise the Carina platform in China and prepare for international growth. This round was co-led by Guolian Capital and INCE Capital, with additional backing from King Star Med and LongRiver Investments.
